Welcome to industryreportstore.com

Need help? +44(0)20 7936 6830

Melanoma - Pipeline Review, H2 2016

By: Global Markets Direct
, Published: Dec-2016
, Product code: GMDHC8868IDB
Key Insights
    • The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
    • The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    • The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
    • The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    • The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)

Companies mentioned in this product:

4SC AG AB Science SA AbbVie Inc Abivax SA Acetylon Pharmaceuticals Inc Adamis Pharmaceuticals Corp Adaptimmune Therapeutics Plc Adicet Bio Inc Aduro BioTech Inc Advanced Cancer Therapeutics Advaxis Inc Aeterna Zentaris Inc Affichem SA Agalimmune Ltd Agenus Inc Agilvax Inc AGV Discovery SAS AIMM Therapeutics BV Alethia Biotherapeutics Inc Altor BioScience Corp Amgen Inc Anavex Life Sciences Corp Angimmune LLC Antibe Therapeutics Inc Antigen Express Inc APEIRON Biologics AG Apexigen Inc Aphios Corp APO-T BV Apogenix GmbH Aposense Ltd Aptose Biosciences Inc Arisaph Pharmaceuticals Inc ARMO Biosciences Inc Array BioPharma Inc Asana BioSciences LLC Astellas Pharma Inc Astex Pharmaceuticals Inc AstraZeneca Plc Aurigene Discovery Technologies Ltd Azaya Therapeutics Inc Basilea Pharmaceutica Ltd Batu Biologics Inc Bayer AG BeiGene Ltd Beijing Kawin Technology Share-Holding Co Ltd Bellicum Pharmaceuticals Inc BerGenBio AS Bio-Cancer Treatment International Ltd Biocad Biogazelle NV Biogenomics Ltd BioLineRx Ltd Bioncotech Therapeutics SL Bionomics Ltd BioNTech AG Biothera Pharmaceutical Inc Biovista Inc Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Calithera Biosciences Inc Can-Fite BioPharma Ltd CCRP Therapeutics GmbH Cellceutix Corp Celldex Therapeutics Inc Celprogen Inc Celyad SA Checkmate Pharmaceuticals Inc Chipscreen Biosciences Ltd Chugai Pharmaceutical Co Ltd Cipher Pharmaceuticals Inc Cornerstone Pharmaceuticals Inc Cortice Biosciences Inc Corvus Pharmaceuticals Inc CytomX Therapeutics Inc Cytune Pharma SAS CyTuVax BV CZ BioMed Corp Daiichi Sankyo Company Ltd Deciphera Pharmaceuticals LLC DEKK-TEC Inc Dicerna Pharmaceuticals Inc DormaTarg Inc Dynavax Technologies Corp Eisai Co Ltd Eli Lilly and Company Elsalys Biotech SAS Ensol Biosciences Inc EntreChem SL eTheRNA Immunotherapies NV Evelo Therapeutics Inc Exelixis Inc F. Hoffmann-La Roche Ltd Faes Farma SA Five Prime Therapeutics Inc Formune SL Galapagos NV Galectin Therapeutics Inc Genelux Corp Genocea Biosciences Inc Genzyme Corp GlaxoSmithKline Plc Gradalis Inc GreenPeptide Co Ltd Hadasit Medical Research Services & Development Ltd HanAll Biopharma Co Ltd Hanmi Pharmaceuticals Co Ltd Heat Biologics Inc HEC Pharm Co Ltd Hemispherx Biopharma Inc Histogen Inc Horizon Pharma Plc Humorigin Biotechnology Corp Idera Pharmaceuticals Inc Ignyta Inc Immodulon Therapeutics Ltd Immune Design Corp Immune Response BioPharma Inc ImmunGene Inc Immunocore Ltd ImmunoGen Inc Immupharma Plc ImmuRx Inc IMPACT Therapeutics Inc Imugene Ltd Incuron LLC Incyte Corp Infinity Pharmaceuticals Inc Inovio Pharmaceuticals Inc InteRNA Technologies BV IO Biotech ApS JHL Biotech Inc Jiangsu Hengrui Medicine Co Ltd Johnson & Johnson KaloBios Pharmaceuticals Inc Kancera AB Karyopharm Therapeutics Inc Kite Pharma Inc Kura Oncology Inc Lentigen Technology Inc Life Science Pharmaceuticals Inc Lindis Biotech GmbH Lion Biotechnologies Inc Lipotek Pty Ltd Loxo Oncology, Inc. Lupin Ltd Lytix Biopharma AS MacroGenics Inc Magnus Life Ltd MaxiVAX SA MediaPharma srl Medicenna Therapeutics Inc MedImmune LLC Medisyn Technologies Inc Medivation Inc MELEMA Pharma GmbH Merck & Co Inc Merck KGaA Millennium Pharmaceuticals Inc Modulate Therapeutics Inc Molecular Templates Inc Moleculin Biotech Inc Morphotek Inc Nektar Therapeutics Neonc Technologies Inc Nerviano Medical Sciences Srl Neumedicines Inc NewLink Genetics Corp NormOxys Inc Northwest Biotherapeutics Inc Novartis AG Novogen Ltd Omeros Corp Oncology Research International Ltd Oncolys BioPharma Inc Oncolytics Biotech Inc OncoNOx ApS OncoSec Medical Inc OncoTartis Inc Oncovir Inc Onxeo SA Orega Biotech SAS OSE Immunotherapeutics Pacific Northwest Biotechnology LLC Patrys Ltd PepTx Inc PepVax Inc Pfizer Inc Pharmicell Co Ltd Pharminox Ltd Pharmis Biofarmaceutica Lda Philogen SpA PinCell srl Pivotal BioSciences Inc Plexxikon Inc Polaris Pharmaceuticals Inc Polyplus-Transfection SA Prima BioMed Ltd Propanc Health Group Corp Provectus Biopharmaceuticals Inc Provenance Biopharmaceuticals Corp Qu Biologics Inc Reata Pharmaceuticals Inc Recepta Biopharma SA Recombio SL Rexahn Pharmaceuticals Inc Rgenix Inc Rigontec GmbH RXi Pharmaceuticals Corp Sapvax SATT North SAS Scancell Holdings Plc SilaGene Inc Sillajen Biotherapeutics SolaranRx Inc Sorrento Therapeutics Inc Spotlight Innovation Inc Sumitomo Dainippon Pharma Co Ltd Sun Pharma Advanced Research Company Ltd Susavion Biosciences Inc SuviCa Inc Syndax Pharmaceuticals Inc Taiga Biotechnologies Inc TaiRx Inc Taiwan Liposome Company Ltd Takara Bio Inc Takeda Pharmaceutical Company Ltd Takis Srl Tara Immuno-Oncology Therapeutics LLC Targovax ASA TC BioPharm Ltd TetraLogic Pharmaceuticals Theravectys SA Tikcro Technologies Ltd TILT Biotherapeutics Ltd Tiltan Pharma Ltd Tocagen Inc TREAT U SA TVAX Biomedical Inc TyrNovo Ltd UbiVac LLC Ultimovacs AS UNC Health Care Vaccibody AS Vascular Biogenics Ltd Vault Pharma Inc Vaxenta Biotechnologies Vichem Chemie Research Ltd Viralytics Ltd ViraTherapeutics GmbH Virttu Biologics Ltd VLP Therapeutics LLC WntResearch AB X4 Pharmaceuticals Inc ZIOPHARM Oncology Inc
Table of Contents
Table of Contents
Table of Contents 2
Introduction 13
Melanoma Overview 14
Therapeutics Development 15
Melanoma - Therapeutics under Development by Companies 17
Melanoma - Therapeutics under Investigation by Universities/Institutes 38
Melanoma - Pipeline Products Glance 43
Melanoma - Products under Development by Companies 47
Melanoma - Products under Investigation by Universities/Institutes 76
Melanoma - Companies Involved in Therapeutics Development 82
Melanoma - Therapeutics Assessment 338
Drug Profiles 391
Melanoma - Dormant Projects 1537
Melanoma - Discontinued Products 1580
Melanoma - Product Development Milestones 1585
Appendix 1598
Tables and Figures
List of Tables
Number of Products under Development for Melanoma, H2 2016 72
Number of Products under Development for Melanoma - Comparative Analysis, H2 2016 73
Number of Products under Development by Companies, H2 2016 74
Number of Products under Development by Companies, H2 2016 (Contd..1) 75
Number of Products under Development by Companies, H2 2016 (Contd..2) 76
Number of Products under Development by Companies, H2 2016 (Contd..3) 77
Number of Products under Development by Companies, H2 2016 (Contd..4) 78
Number of Products under Development by Companies, H2 2016 (Contd..5) 79
Number of Products under Development by Companies, H2 2016 (Contd..6) 80
Number of Products under Development by Companies, H2 2016 (Contd..7) 81
Number of Products under Development by Companies, H2 2016 (Contd..8) 82
Number of Products under Development by Companies, H2 2016 (Contd..9) 83
Number of Products under Development by Companies, H2 2016 (Contd..10) 84
Number of Products under Development by Companies, H2 2016 (Contd..11) 85
Number of Products under Development by Companies, H2 2016 (Contd..12) 86
Number of Products under Development by Companies, H2 2016 (Contd..13) 87
Number of Products under Development by Companies, H2 2016 (Contd..14) 88
Number of Products under Development by Companies, H2 2016 (Contd..15) 89
Number of Products under Development by Companies, H2 2016 (Contd..16) 90
Number of Products under Development by Companies, H2 2016 (Contd..17) 91
Number of Products under Development by Companies, H2 2016 (Contd..18) 92
Number of Products under Development by Companies, H2 2016 (Contd..19) 93
Number of Products under Development by Companies, H2 2016 (Contd..20) 94
Number of Products under Investigation by Universities/Institutes, H2 2016 95
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 96
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 97
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 98
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 99
Comparative Analysis by Late Stage Development, H2 2016 100
Comparative Analysis by Clinical Stage Development, H2 2016 101
Comparative Analysis by Early Stage Development, H2 2016 102
Comparative Analysis by Unknown Stage Development, H2 2016 103
Products under Development by Companies, H2 2016 104
Products under Development by Companies, H2 2016 (Contd..1) 105
Products under Development by Companies, H2 2016 (Contd..2) 106
Products under Development by Companies, H2 2016 (Contd..3) 107
Products under Development by Companies, H2 2016 (Contd..4) 108
Products under Development by Companies, H2 2016 (Contd..5) 109
Products under Development by Companies, H2 2016 (Contd..6) 110
Products under Development by Companies, H2 2016 (Contd..7) 111
Products under Development by Companies, H2 2016 (Contd..8) 112
Products under Development by Companies, H2 2016 (Contd..9) 113
Products under Development by Companies, H2 2016 (Contd..10) 114
Products under Development by Companies, H2 2016 (Contd..11) 115
Products under Development by Companies, H2 2016 (Contd..12) 116
Products under Development by Companies, H2 2016 (Contd..13) 117
Products under Development by Companies, H2 2016 (Contd..14) 118
Products under Development by Companies, H2 2016 (Contd..15) 119
Products under Development by Companies, H2 2016 (Contd..16) 120
Products under Development by Companies, H2 2016 (Contd..17) 121
Products under Development by Companies, H2 2016 (Contd..18) 122
Products under Development by Companies, H2 2016 (Contd..19) 123
Products under Development by Companies, H2 2016 (Contd..20) 124
Products under Development by Companies, H2 2016 (Contd..21) 125
Products under Development by Companies, H2 2016 (Contd..22) 126
Products under Development by Companies, H2 2016 (Contd..23) 127
Products under Development by Companies, H2 2016 (Contd..24) 128
Products under Development by Companies, H2 2016 (Contd..25) 129
Products under Development by Companies, H2 2016 (Contd..26) 130
Products under Development by Companies, H2 2016 (Contd..27) 131
Products under Development by Companies, H2 2016 (Contd..28) 132
Products under Investigation by Universities/Institutes, H2 2016 133
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 134
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 135
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 136
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 137
Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 138
Melanoma - Pipeline by 4SC AG, H2 2016 139
Melanoma - Pipeline by AB Science SA, H2 2016 140
Melanoma - Pipeline by AbbVie Inc, H2 2016 141
Melanoma - Pipeline by Abivax SA, H2 2016 142
Melanoma - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 143
Melanoma - Pipeline by Adamis Pharmaceuticals Corp, H2 2016 144
Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 145
Melanoma - Pipeline by Adicet Bio Inc, H2 2016 146
Melanoma - Pipeline by Aduro BioTech Inc, H2 2016 147
Melanoma - Pipeline by Advanced Cancer Therapeutics, H2 2016 148
Melanoma - Pipeline by Advaxis Inc, H2 2016 149
Melanoma - Pipeline by Aeterna Zentaris Inc, H2 2016 150
Melanoma - Pipeline by Affichem SA, H2 2016 151
Melanoma - Pipeline by Agalimmune Ltd, H2 2016 152
Melanoma - Pipeline by Agenus Inc, H2 2016 153
Melanoma - Pipeline by Agilvax Inc, H2 2016 154
Melanoma - Pipeline by AGV Discovery SAS, H2 2016 155
Melanoma - Pipeline by AIMM Therapeutics BV, H2 2016 156
Melanoma - Pipeline by Alethia Biotherapeutics Inc, H2 2016 157
Melanoma - Pipeline by Altor BioScience Corp, H2 2016 158
Melanoma - Pipeline by Amgen Inc, H2 2016 159
Melanoma - Pipeline by Anavex Life Sciences Corp, H2 2016 160
Melanoma - Pipeline by Angimmune LLC, H2 2016 161
Melanoma - Pipeline by Antibe Therapeutics Inc, H2 2016 162
Melanoma - Pipeline by Antigen Express Inc, H2 2016 163
Melanoma - Pipeline by APEIRON Biologics AG, H2 2016 164
Melanoma - Pipeline by Apexigen Inc, H2 2016 165
Melanoma - Pipeline by Aphios Corp, H2 2016 166
Melanoma - Pipeline by APO-T BV, H2 2016 167
Melanoma - Pipeline by Apogenix GmbH, H2 2016 168
Melanoma - Pipeline by Aposense Ltd, H2 2016 169
Melanoma - Pipeline by Aptose Biosciences Inc, H2 2016 170
Melanoma - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016 171
Melanoma - Pipeline by ARMO Biosciences Inc, H2 2016 172
Melanoma - Pipeline by Array BioPharma Inc, H2 2016 173
Melanoma - Pipeline by Asana BioSciences LLC, H2 2016 174
Melanoma - Pipeline by Astellas Pharma Inc, H2 2016 175
Melanoma - Pipeline by Astex Pharmaceuticals Inc, H2 2016 176
Melanoma - Pipeline by AstraZeneca Plc, H2 2016 177
Melanoma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 178
Melanoma - Pipeline by Azaya Therapeutics Inc, H2 2016 179
Melanoma - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 180
Melanoma - Pipeline by Batu Biologics Inc, H2 2016 181
Melanoma - Pipeline by Bayer AG, H2 2016 182
Melanoma - Pipeline by BeiGene Ltd, H2 2016 183
Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016 184
Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 185
Melanoma - Pipeline by BerGenBio AS, H2 2016 186
Melanoma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 187
Melanoma - Pipeline by Biocad, H2 2016 188
Melanoma - Pipeline by Biogazelle NV, H2 2016 189
Melanoma - Pipeline by Biogenomics Ltd, H2 2016 190
Melanoma - Pipeline by BioLineRx Ltd, H2 2016 191
Melanoma - Pipeline by Bioncotech Therapeutics SL, H2 2016 192
Melanoma - Pipeline by Bionomics Ltd, H2 2016 193
Melanoma - Pipeline by BioNTech AG, H2 2016 194
Melanoma - Pipeline by Biothera Pharmaceutical Inc, H2 2016 195
Melanoma - Pipeline by Biovista Inc, H2 2016 196
Melanoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 197
Melanoma - Pipeline by Boston Biomedical Inc, H2 2016 198
Melanoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 199
Melanoma - Pipeline by Calithera Biosciences Inc, H2 2016 200
Melanoma - Pipeline by Can-Fite BioPharma Ltd, H2 2016 201
Melanoma - Pipeline by CCRP Therapeutics GmbH, H2 2016 202
Melanoma - Pipeline by Cellceutix Corp, H2 2016 203
Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2016 204
Melanoma - Pipeline by Celprogen Inc, H2 2016 205
Melanoma - Pipeline by Celyad SA, H2 2016 206
Melanoma - Pipeline by Checkmate Pharmaceuticals Inc, H2 2016 207
Melanoma - Pipeline by Chipscreen Biosciences Ltd, H2 2016 208
Melanoma - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 209
Melanoma - Pipeline by Cipher Pharmaceuticals Inc, H2 2016 210
Melanoma - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 211
Melanoma - Pipeline by Cortice Biosciences Inc, H2 2016 212
Melanoma - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 213
Melanoma - Pipeline by CytomX Therapeutics Inc, H2 2016 214
Melanoma - Pipeline by Cytune Pharma SAS, H2 2016 215
Melanoma - Pipeline by CyTuVax BV, H2 2016 216
Melanoma - Pipeline by CZ BioMed Corp, H2 2016 217
Melanoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 218
Melanoma - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 219
Melanoma - Pipeline by DEKK-TEC Inc, H2 2016 220
Melanoma - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 221
Melanoma - Pipeline by DormaTarg Inc, H2 2016 222
Melanoma - Pipeline by Dynavax Technologies Corp, H2 2016 223
Melanoma - Pipeline by Eisai Co Ltd, H2 2016 224
Melanoma - Pipeline by Eli Lilly and Company, H2 2016 225
Melanoma - Pipeline by Elsalys Biotech SAS, H2 2016 226
Melanoma - Pipeline by Ensol Biosciences Inc, H2 2016 227
Melanoma - Pipeline by EntreChem SL, H2 2016 228
Melanoma - Pipeline by eTheRNA Immunotherapies NV, H2 2016 229
Melanoma - Pipeline by Evelo Therapeutics Inc, H2 2016 230
Melanoma - Pipeline by Exelixis Inc, H2 2016 231
Melanoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 232
Melanoma - Pipeline by Faes Farma SA, H2 2016 233
Melanoma - Pipeline by Five Prime Therapeutics Inc, H2 2016 234
Melanoma - Pipeline by Formune SL, H2 2016 235
Melanoma - Pipeline by Galapagos NV, H2 2016 236
Melanoma - Pipeline by Galectin Therapeutics Inc, H2 2016 237
Melanoma - Pipeline by Genelux Corp, H2 2016 238
Melanoma - Pipeline by Genocea Biosciences Inc, H2 2016 239
Melanoma - Pipeline by Genzyme Corp, H2 2016 240
Melanoma - Pipeline by GlaxoSmithKline Plc, H2 2016 241

List of Figures
Number of Products under Development for Melanoma, H2 2016 72
Number of Products under Development for Melanoma - Comparative Analysis, H2 2016 73
Number of Products under Development by Companies, H2 2016 74
Number of Products under Investigation by Universities/Institutes, H2 2016 95
Comparative Analysis by Late Stage Development, H2 2016 100
Comparative Analysis by Clinical Stage Development, H2 2016 101
Comparative Analysis by Early Stage Products, H2 2016 102
Assessment by Monotherapy Products, H2 2016 395
Assessment by Combination Products, H2 2016 396
Number of Products by Top 10 Targets, H2 2016 397
Number of Products by Stage and Top 10 Targets, H2 2016 397
Number of Products by Top 10 Mechanism of Actions, H2 2016 421
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 421
Number of Products by Top 10 Routes of Administration, H2 2016 444
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 444
Number of Products by Top 10 Molecule Types, H2 2016 446
Number of Products by Stage and Top 10 Molecule Types, H2 2016 446
Sample Pages

Request Sample Pages

Melanoma - Pipeline Review, H2 2016
By: Global Markets Direct
Published: Dec 2016
Contact Details


Download Brochure

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma – Pipeline Review, H2 2016, provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 17, 92, 111, 3, 208, 24 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 14, 10, 62 and 12 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Synopsis

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)

Reasons To Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Quick Overview

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma – Pipeline Review, H2 2016, provides an overview of the Melanoma (Oncology) pipeline landscape.

More information about Melanoma - Pipeline Review, H2 2016

For more information on this report or to speak to one of our experts

Call us on +44(0)20 7936 6830 or Email us

mail

For more information
on this report or to speak to one of our experts

Email us or call us on
+44(0)20 7936 6830

Purchase

Site License - This allows anybody within a business at the same site to view the report.

Single-user - This allows only one person to view the report.

Enterprise License -  This allows anybody globally within the organisation to view the report.

Preview Report

For a free preview of this report please complete our simple form.

Request
mail

Read our latest
Industry Insights Blog
and stay informed